BridgeBio says FDA accepts encaleret NDA for ADH1, sets May 8, 2027 PDUFA date

• FDA accepted BridgeBio’s NDA for encaleret in autosomal dominant hypocalcemia type 1, granting Priority Review.
• PDUFA target action date set for May 8, 2027.
• Marketing authorization application filed with the EMA for the same indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610111142PRIMZONEFULLFEED9843312) on October 11, 2026, and is solely responsible for the information contained therein.